An investigational Lyme disease vaccine, LB6V, demonstrated a vaccine efficacy (VE) rate of over 70% in a phase III trial. The trial involved approximately 9,400 participants aged 5 years and older across Europe, Canada, and the U.S. who were at increased Lyme disease risk.
Key Clinical Findings
Participants received four doses of the vaccine or a placebo over three Lyme disease seasons (2022-2025). The primary efficacy endpoint was vaccine efficacy against Lyme disease from 28 days after the fourth dose through the end of the Lyme disease season. With a modified intent-to-treat analysis, the VE rate reached 74.8% (95% CI 21.7-93.9). Four participants who received the vaccine developed Lyme disease compared with 15 in the placebo group. Adverse events occurred in 58.8% of LB6V recipients versus 52.6% of the placebo group, with similar rates of fatigue, headache, muscle pain, and joint pain observed in vaccine recipients. The VE rate decreased from 73.2% in the second season to 18.6% in the third season, accompanied by a significant decline in antibody titers against Borrelia burgdorferi. Median patient age was 47 years, with 52% female and 95.8% white. 97% of participants had at least two Lyme disease risk factors. The vaccine targets six serotypes across four Borrelia species. Formerly known as VLA15, LB6V generated immunogenicity and appeared safe in two phase II trials. Paul Auwaerter, MD suggested that an annual booster before a Lyme disease season would likely be beneficial, given the observed decline in antibody titers. The relationship between vaccine efficacy and antibody titers between seasons two and three shows that these titers are associated with a lower risk of Lyme disease and may prove to be a potential basis moving ahead for immunobridging studies.